Literature DB >> 19615450

Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects.

Xue Hua1, Suh Lee, Igor Yanovsky, Alex D Leow, Yi-Yu Chou, April J Ho, Boris Gutman, Arthur W Toga, Clifford R Jack, Matt A Bernstein, Eric M Reiman, Danielle J Harvey, John Kornak, Norbert Schuff, Gene E Alexander, Michael W Weiner, Paul M Thompson.   

Abstract

Tensor-based morphometry (TBM) is a powerful method to map the 3D profile of brain degeneration in Alzheimer's disease (AD) and mild cognitive impairment (MCI). We optimized a TBM-based image analysis method to determine what methodological factors, and which image-derived measures, maximize statistical power to track brain change. 3D maps, tracking rates of structural atrophy over time, were created from 1030 longitudinal brain MRI scans (1-year follow-up) of 104 AD patients (age: 75.7+/-7.2 years; MMSE: 23.3+/-1.8, at baseline), 254 amnestic MCI subjects (75.0+/-7.2 years; 27.0+/-1.8), and 157 healthy elderly subjects (75.9+/-5.1 years; 29.1+/-1.0), as part of the Alzheimer's Disease Neuroimaging Initiative (ADNI). To determine which TBM designs gave greatest statistical power, we compared different linear and nonlinear registration parameters (including different regularization functions), and different numerical summary measures derived from the maps. Detection power was greatly enhanced by summarizing changes in a statistically-defined region-of-interest (ROI) derived from an independent training sample of 22 AD patients. Effect sizes were compared using cumulative distribution function (CDF) plots and false discovery rate methods. In power analyses, the best method required only 48 AD and 88 MCI subjects to give 80% power to detect a 25% reduction in the mean annual change using a two-sided test (at alpha=0.05). This is a drastic sample size reduction relative to using clinical scores as outcome measures (619 AD/6797 MCI for the ADAS-Cog, and 408 AD/796 MCI for the Clinical Dementia Rating sum-of-boxes scores). TBM offers high statistical power to track brain changes in large, multi-site neuroimaging studies and clinical trials of AD.

Entities:  

Mesh:

Year:  2009        PMID: 19615450      PMCID: PMC2971697          DOI: 10.1016/j.neuroimage.2009.07.011

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  96 in total

1.  Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain.

Authors:  E T Bullmore; J Suckling; S Overmeyer; S Rabe-Hesketh; E Taylor; M J Brammer
Journal:  IEEE Trans Med Imaging       Date:  1999-01       Impact factor: 10.048

2.  Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain.

Authors:  Bruce Fischl; David H Salat; Evelina Busa; Marilyn Albert; Megan Dieterich; Christian Haselgrove; Andre van der Kouwe; Ron Killiany; David Kennedy; Shuna Klaveness; Albert Montillo; Nikos Makris; Bruce Rosen; Anders M Dale
Journal:  Neuron       Date:  2002-01-31       Impact factor: 17.173

3.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.

Authors:  C R Jack; R C Petersen; Y C Xu; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; S C Waring; E G Tangalos; E Kokmen
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

4.  MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD.

Authors:  C R Jack; M Slomkowski; S Gracon; T M Hoover; J P Felmlee; K Stewart; Y Xu; M Shiung; P C O'Brien; R Cha; D Knopman; R C Petersen
Journal:  Neurology       Date:  2003-01-28       Impact factor: 9.910

Review 5.  Looking backward to move forward: early detection of neurodegenerative disorders.

Authors:  Steven T DeKosky; Kenneth Marek
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

6.  Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls.

Authors:  Jonathan H Morra; Zhuowen Tu; Liana G Apostolova; Amity E Green; Christina Avedissian; Sarah K Madsen; Neelroop Parikshak; Arthur W Toga; Clifford R Jack; Norbert Schuff; Michael W Weiner; Paul M Thompson
Journal:  Neuroimage       Date:  2008-11-08       Impact factor: 6.556

7.  An estimate of the worldwide prevalence and direct costs of dementia in 2003.

Authors:  A Wimo; L Jonsson; B Winblad
Journal:  Dement Geriatr Cogn Disord       Date:  2006-01-09       Impact factor: 2.959

8.  Absence of cognitive impairment or decline in preclinical Alzheimer's disease.

Authors:  W P Goldman; J L Price; M Storandt; E A Grant; D W McKeel; E H Rubin; J C Morris
Journal:  Neurology       Date:  2001-02-13       Impact factor: 9.910

9.  Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry.

Authors:  April J Ho; Xue Hua; Suh Lee; Alex D Leow; Igor Yanovsky; Boris Gutman; Ivo D Dinov; Natasha Leporé; Jason L Stein; Arthur W Toga; Clifford R Jack; Matt A Bernstein; Eric M Reiman; Danielle J Harvey; John Kornak; Norbert Schuff; Gene E Alexander; Michael W Weiner; Paul M Thompson
Journal:  Hum Brain Mapp       Date:  2010-04       Impact factor: 5.038

Review 10.  Drug discovery and the prevention of Alzheimer's disease.

Authors:  Howard Fillit
Journal:  Alzheimers Dement       Date:  2007-12-21       Impact factor: 21.566

View more
  76 in total

1.  The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes.

Authors:  Laurel A Beckett; Danielle J Harvey; Anthony Gamst; Michael Donohue; John Kornak; Hao Zhang; Julie H Kuo
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

2.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core.

Authors:  William J Jagust; Dan Bandy; Kewei Chen; Norman L Foster; Susan M Landau; Chester A Mathis; Julie C Price; Eric M Reiman; Daniel Skovronsky; Robert A Koeppe
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

Review 3.  Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative.

Authors:  Clifford R Jack; Matt A Bernstein; Bret J Borowski; Jeffrey L Gunter; Nick C Fox; Paul M Thompson; Norbert Schuff; Gunnar Krueger; Ronald J Killiany; Charles S Decarli; Anders M Dale; Owen W Carmichael; Duygu Tosun; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

Review 4.  The Alzheimer's disease neuroimaging initiative: progress report and future plans.

Authors:  Michael W Weiner; Paul S Aisen; Clifford R Jack; William J Jagust; John Q Trojanowski; Leslie Shaw; Andrew J Saykin; John C Morris; Nigel Cairns; Laurel A Beckett; Arthur Toga; Robert Green; Sarah Walter; Holly Soares; Peter Snyder; Eric Siemers; William Potter; Patricia E Cole; Mark Schmidt
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

5.  Gray matter network associated with risk for Alzheimer's disease in young to middle-aged adults.

Authors:  Gene E Alexander; Kaitlin L Bergfield; Kewei Chen; Eric M Reiman; Krista D Hanson; Lan Lin; Daniel Bandy; Richard J Caselli; James R Moeller
Journal:  Neurobiol Aging       Date:  2012-03-08       Impact factor: 4.673

Review 6.  Quantitative structural MRI for early detection of Alzheimer's disease.

Authors:  Linda K McEvoy; James B Brewer
Journal:  Expert Rev Neurother       Date:  2010-11       Impact factor: 4.618

Review 7.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2011-11-02       Impact factor: 21.566

8.  Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative.

Authors:  Joshua D Grill; Lijie Di; Po H Lu; Cathy Lee; John Ringman; Liana G Apostolova; Nicole Chow; Omid Kohannim; Jeffrey L Cummings; Paul M Thompson; David Elashoff
Journal:  Neurobiol Aging       Date:  2012-04-13       Impact factor: 4.673

9.  Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort.

Authors:  Shannon L Risacher; Li Shen; John D West; Sungeun Kim; Brenna C McDonald; Laurel A Beckett; Danielle J Harvey; Clifford R Jack; Michael W Weiner; Andrew J Saykin
Journal:  Neurobiol Aging       Date:  2010-08       Impact factor: 4.673

10.  Bias in estimation of hippocampal atrophy using deformation-based morphometry arises from asymmetric global normalization: an illustration in ADNI 3 T MRI data.

Authors:  Paul A Yushkevich; Brian B Avants; Sandhitsu R Das; John Pluta; Murat Altinay; Caryne Craige
Journal:  Neuroimage       Date:  2009-12-31       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.